Mutant KLF4 Protein for Higher-Efficiency iPS Reprogramming
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The low production efficiency of induced pluripotent stem cells (iPS cells) poses a significant obstacle to clinical applications, particularly due to the low efficiency of reprogramming somatic cells using conventional factors like OCT3/4, SOX2, and C-MYC, which limits the rapid production of transplant tissues and increases the burden on patients.
Innovation Solution
Development of a mutant KLF protein with specific amino acid substitutions, such as S349A, L356A, S500A, or L507A, to enhance the reprogramming efficiency of somatic cells when combined with other factors like OCT3/4, SOX2, and C-MYC, using a method that includes cultivation with additional factors and selection steps.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional reprogramming factors (OCT3/4, SOX2, KLF4, C-MYC) are used to induce iPS cells, then reprogramming can be achieved, but production efficiency remains extremely low (less than 1%)
Solution Approach 1:
The invention modifies the amino acid sequence of the KLF4 protein by substituting specific residues (S349A, L356A, S500A, L507A) to enhance its transcriptional activity. This parameter change in the protein structure directly improves reprogramming efficiency, transforming the low-efficiency conventional method into a high-efficiency method that can produce sufficient iPS cells rapidly for clinical applications
2Reliability
If C-MYC is substituted with another factor to improve safety and reduce tumorigenesis risk, then safety is improved, but production efficiency of iPS cells is extremely lowered
Solution Approach 1:
The enhanced KLF4 mutant compensates for the loss of C-MYC activity through its improved transcriptional potency. By optimizing the amino acid sequence of KLF4, the invention achieves both safety (by eliminating or reducing C-MYC) and high productivity, resolving the trade-off between safety and production efficiency
Solution Approach 2:
The invention creates an asymmetric reprogramming factor combination by heavily optimizing KLF4 while reducing or eliminating C-MYC. This asymmetric approach allows the enhanced KLF4 to carry the reprogramming burden alone or with minimal assistance, achieving both safety and efficiency
3Quantity of substance
If a large number of somatic cells are used for iPS cell production, then sufficient iPS cells can be obtained, but the burden on the patient's body increases
Solution Approach 1:
The enhanced transcriptional activity of the KLF4 mutant dramatically improves reprogramming efficiency, allowing sufficient numbers of iPS cells to be generated from minimal starting materials. This parameter change in protein efficiency directly reduces the quantity of somatic cells needed, thereby reducing patient burden
Data Source
AI summary
There is provided a mutant KLF protein that can induce reprogramming of a somatic cell at a higher efficiency than a KLF protein having a natural amino acid sequence. There is also provided a method for efficiently producing an iPS cell by using the mutant KLF protein. There is provided a mutant KLF protein having an amino acid substitution, or a peptide fragment thereof containing the amino acid substitution.